Opening of Bids - WWTP Electrical Improvements Proj No 117-132 - J. Ranck Electric Inc

Home Browse Search

during the prooadure to ensure privacy to the employee and prevent distraction of the collector? Also, are limited -access signs posted [§40.43(c)]? 35 0.02.c. Are procedures in place to assure the collector maintains personal control over each specimen and CCF throughout the collection process and to prevent unauthorized personnel from entering any part of the site in which urine specimens are collected or stored [§40.43(dx5) and §40.43(e)]? 36 0.02.d. Is the current Federal Drug Testing Custody and Control Form (CCF) or equivalent being used [§40.45]? 37 0.02.e. Is a collection kit used that meets the requirements of Appendix A to Part 40 [§40.49]? 38 0.03.a. Do collection site personnel explain the basic collection procedure to the employee, including showing the employee the instructions on the back of the CCF [§40.61(e)]? 39 0.03.b. Do collection site personnel provide the donor with an Individually wrapped or sealed collection container from the collection kit materials [§40.63(c)]9 40 0.t13«c... Are precautions taken to ensure that unaduttarsted specimens are obtained and correctly identified that most the following requirements: 1) sluing agents in toilet tank and all water sources secure [§40.43(b)(11) and (2)); 2) individual positively Identified (photo ID, etc.) [§40.61(c)]; 3) Proper authority contacted if individual fails to arrive at the assigned time [§40.61(a)]; 4) The donor shall remove any unnecessary outer garments. Pumas or briefcases shall remain with outer garments [§40.61(f)]; 5) Donor shall wash and dry his/her hands [§40.83(b)); 6) To the greatest extent possible, the collector must keep an employee's collection container within view of both himself/herself and the employee between the time the employee has urinated and the specimen is sealed [§40.43(d)(2)]; and, 7) Any unusual behavior noted on the CCF [§40.63(e)] 41 0.03.d. Are procedures being followed at the collection site after the specimen has been provided In compliance with the requirements of §40.65 42 0.03.e. Have provisions been made If the donor is unable to provide at least 45 milliliters of urine [§40.65(a)]? 43 0.031. Are procedures in place for immediately collecting urine specimens under direct observation for the situations identified In §40.67(c). As of August 31, 2009, verify that all collections for return -to -duty and follow-up testing were performed under DER directed direct observation [§40.67(b)] 44 0.03.9. Are same gender collection personnel used if a collection is monitored under direct observation by non -medical personnel [§40.89(g)] 45 0.03.h. Is the CCF properly executed by authorized collection site personnel upon receipt and transfer of a urine specimen [§40.73(a)] 46 D.01.a. Verify drug testing laboratory used for all testing required by Part 40 and Part 199 Is certified by the Department of Health and Human Services (HHS) [§40.81(a) and §199.107(a)]. 47 0.01.c. Verify laboratory results are reported directly, and only, to the MRO at his or her place of business. Results must not be reported to or through the DER or a service agent (e.g., CfTPA) [§40.97(b)]. 48 D.01 b. Verify drug testing laboratory only tests for the following five drugs or classes of drugs in a DOT drug test. (The laboratories must not test "DOT specimens" for any other drugs): (a) Marijuana metabolites; (b) Cocaine metabolites; (c) Amphetamines; (d) Opiate metabolites; and (a) Phencyclidine (PCP)1§40.3, §40.85 and §199.3]. 49 0.01.d. Verify laboratory testing the primary specimen will retain a specimen that was reported with positive, adulterated, substituted, or invalid results for a minimum of one year. The specimen must be kept in secure, long-term, frozen storage in accordance with HHS requirements [§40.99 and §199.111(a)]. 50 D.03.a. Verify laboratory retains all records pertaining to each employee urine specimen for a minimum of two years and also keeps for two years employer -specific data required In §40.111 [§40.1091. 51 D.03.b. Verify laboratory transmits an aggregate statistical summary to the Company per Part 40, Appendix B, on a semi-annual basis. 52 D.02A. If the Company or CITPA, used by the Company, has an aggregate of 2000 or more DOT -covered employees, blind specimens are submitted to the laboratories used. If the Company or C/TPA has an aggregate of fewer than 2000 DOT -covered employees, DOT does not require them to provide blind specimens [W.103(a)]. 53 E.01.a. Verify that an MRO is designated or appointed by the Anti -Drug Plan [§199,109(a)]. 54 E.01.b. Verify that the MRO provides quality assurance reviews of the drug testing process, including ensuring the review of the Custody and Control Form (CCF) on all specimen collections [§40.123(b)]. 55 E.01.c. Verify that the MRO performs the review functions required by §40.127 for negative drug test results received from a laboratory, prior to verifying the result and releasing it to the Designated Employer Representative (DER). 56 E.01.d. Verify that the MRO performs the review functions required by §40.129 for confirmed positive, adulterated, substituted, or Invalid drug test results received from a laboratory, prior to verifying the result and releasing It to the DER. In addition, the MRO must determine whether there is a legitimate medical explanation for confirmed positive, adulterated, substituted, and Invalid drug test results from the laboratory [§40.123(c)]. J. RANCK ELECTRIC, INC. PHMSA DRUGIALCOHOL PLAN _ 20'10 NATIONAL COMPLIANCE MANAGEMENT SERVICE, INC. (NCKIS) 42